198 related articles for article (PubMed ID: 24676237)
21. In vitro susceptibilities of bloodstream isolates of Candida spp.: results from a multicenter active surveillance program in Andalusia.
Flórez C; Martín-Mazuelos E; Ruiz M; Cisneros JM; Herrero M; García MV; Márquez M; Porras J; Martín P; Gamero C; Castón JJ;
Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):518-22. PubMed ID: 19477048
[TBL] [Abstract][Full Text] [Related]
22. In vitro antifungal susceptibility of clinical isolates of Arthrographis kalrae, a poorly known opportunistic fungus.
Sandoval-Denis M; Giraldo A; Sutton DA; Fothergill AW; Guarro J
Mycoses; 2014 Apr; 57(4):247-8. PubMed ID: 24147779
[TBL] [Abstract][Full Text] [Related]
23. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.
Pfaller MA; Castanheira M; Messer SA; Rhomberg PR; Jones RN
Diagn Microbiol Infect Dis; 2014 Jun; 79(2):198-204. PubMed ID: 24736096
[TBL] [Abstract][Full Text] [Related]
24. Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents.
Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzón A; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2003 Jul; 47(7):2339-41. PubMed ID: 12821493
[TBL] [Abstract][Full Text] [Related]
25. The echinocandins.
Cappelletty D; Eiselstein-McKitrick K
Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
[TBL] [Abstract][Full Text] [Related]
26. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
[TBL] [Abstract][Full Text] [Related]
28. [In vitro antifungal susceptibility profile of Scopulariopsis brevicaulis isolated from onychomycosis].
Carrillo-Muñoz AJ; Tur-Tur C; Cárdenes D; Rojas F; Giusiano G
Rev Esp Quimioter; 2015 Aug; 28(4):210-3. PubMed ID: 26200030
[TBL] [Abstract][Full Text] [Related]
29. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003.
Cuenca-Estrella M; Rodriguez D; Almirante B; Morgan J; Planes AM; Almela M; Mensa J; Sanchez F; Ayats J; Gimenez M; Salvado M; Warnock DW; Pahissa A; Rodriguez-Tudela JL;
J Antimicrob Chemother; 2005 Feb; 55(2):194-9. PubMed ID: 15618284
[TBL] [Abstract][Full Text] [Related]
30. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
31. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of broth microdilution and E-test methods for the antifungal susceptibility testing of Candida spp. strains isolated from blood cultures].
Ozcan SK; Mutlu B; Dündar D; Willke A
Mikrobiyol Bul; 2010 Apr; 44(2):263-71. PubMed ID: 20549961
[TBL] [Abstract][Full Text] [Related]
33. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
[TBL] [Abstract][Full Text] [Related]
34. In Vitro Triple Combination of Antifungal Drugs against Clinical Scopulariopsis and Microascus Species.
Yao L; Wan Z; Li R; Yu J
Antimicrob Agents Chemother; 2015 Aug; 59(8):5040-3. PubMed ID: 26014943
[TBL] [Abstract][Full Text] [Related]
35. Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations.
Halliday CL; Chen SC; Kidd SE; van Hal S; Chapman B; Heath CH; Lee A; Kennedy KJ; Daveson K; Sorrell TC; Morrissey CO; Marriott DJ; Slavin MA
Int J Antimicrob Agents; 2016 Oct; 48(4):453-8. PubMed ID: 27562696
[TBL] [Abstract][Full Text] [Related]
36. [In vitro antifungal activity of voriconazole against dermatophytes and superficial isolates of Scopulariopsis brevicaulis].
Carrillo-Muñoz AJ; Cárdenes CD; Carrillo-Orive B; Rodríguez V; Del Valle O; Casals JB; Ezkurra PA; Quindós G
Rev Iberoam Micol; 2005 Jun; 22(2):110-3. PubMed ID: 16107170
[TBL] [Abstract][Full Text] [Related]
37. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
38. Elevated minimum inhibitory concentrations to antifungal drugs prevail in 14 rare species of candidemia-causing Saccharomycotina yeasts.
Stavrou AA; Pérez-Hansen A; Lackner M; Lass-Flörl C; Boekhout T
Med Mycol; 2020 Oct; 58(7):987-995. PubMed ID: 32043147
[TBL] [Abstract][Full Text] [Related]
39. Dihydroorotate dehydrogenase inhibitor olorofim has potent in vitro activity against Microascus/Scopulariopsis, Rasamsonia, Penicillium and Talaromyces species.
Wiederhold NP; Patterson HP; Sanders CJ; Cañete-Gibas C
Mycoses; 2023 Mar; 66(3):242-248. PubMed ID: 36435987
[TBL] [Abstract][Full Text] [Related]
40. Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections.
Carrillo-Muñoz AJ; Quindós G; Ruesga M; Alonso R; del Valle O; Hernández-Molina JM; McNicholas P; Loebenberg D; Santos P
J Antimicrob Chemother; 2005 Mar; 55(3):317-9. PubMed ID: 15705637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
